US4871552A - Hydantoins as animal food supplements - Google Patents

Hydantoins as animal food supplements Download PDF

Info

Publication number
US4871552A
US4871552A US07/174,651 US17465188A US4871552A US 4871552 A US4871552 A US 4871552A US 17465188 A US17465188 A US 17465188A US 4871552 A US4871552 A US 4871552A
Authority
US
United States
Prior art keywords
hydantoin
analogue
hydroxy
food composition
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/174,651
Inventor
Robert W. Bragdon
Roger R. Gaudette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hampshire Chemical Corp
Original Assignee
WR Grace and Co Conn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/911,688 external-priority patent/US4744990A/en
Application filed by WR Grace and Co Conn filed Critical WR Grace and Co Conn
Priority to US07/174,651 priority Critical patent/US4871552A/en
Assigned to W. R. GRACE & CO.-CONN., A CORP. OF CT. reassignment W. R. GRACE & CO.-CONN., A CORP. OF CT. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: BRAGDON, ROBERT W., GAUDETTE, ROGER R.
Assigned to W. R. GRACE & CO.-CONN. reassignment W. R. GRACE & CO.-CONN. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: GRACE MERGER CORP. A CT CORP. (MERGED INTO), W. R. GRACE & CO. A CT. CORP.
Application granted granted Critical
Publication of US4871552A publication Critical patent/US4871552A/en
Assigned to CHASE MANHATTAN BANK (NATIONAL ASSOCIATION), AS COLLATERAL AGENT, THE reassignment CHASE MANHATTAN BANK (NATIONAL ASSOCIATION), AS COLLATERAL AGENT, THE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAMPSHIRE CHEMICAL CORP.
Assigned to HAMPSHIRE CHEMICAL CORP. reassignment HAMPSHIRE CHEMICAL CORP. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: W.R. GRACE & CO.-CONN.
Assigned to CHEMICAL BANK reassignment CHEMICAL BANK ASSIGNMENT FOR SECURITY Assignors: HAMPSHIRE CHEMICAL CORPORATION
Assigned to HAMPSHIRE CHEMICAL CORPORATION reassignment HAMPSHIRE CHEMICAL CORPORATION PATENT RELEASE Assignors: CHASE MANHATTAN BANK, THE
Assigned to HAMPSHIRE CHEMICAL CORP. reassignment HAMPSHIRE CHEMICAL CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHASE MANHATTAN BANK, THE
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/116Heterocyclic compounds
    • A23K20/137Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S426/00Food or edible material: processes, compositions, and products
    • Y10S426/807Poultry or ruminant feed

Definitions

  • This invention relates to the field of animal nutrition.
  • the invention concerns nutritive supplements for warm-blooded animals.
  • Proteins are used to replace tissues, generate hormones, to provide the structural framework of the body (e.g. muscles, tendons, cartilage, etc..) and can also be consumed for energy.
  • Amino acids are the building blocks of proteins. In all living organisms, proteins and their constituent amino acids are continuously metabolized and exist in a dynamic equilibrium in the cells. Approximately 20 amino acids are common constituents of animal proteins. However, eight to ten of these amino acids are essential for the animal's survival. Since the animal's reserves of these essential amino acids are normally depleted within a few hours, the animmal must replenish its supply by ingesting proteins containing appropriate amounts of essential amino acids. The nutritional value of proteins used in aminal feed is therefore a function of the presence of these essential amino acids in proper amounts. However, feeds containing proteins of low nutritional value, i.e.
  • plant proteins such as wheat, corn, and soybeans are commonly fortified with L-lysine, DL-methionine and/or other essential amino acids to upgrade the nutritional value of these common animal feeds.
  • KIC has special properties which distinguish it from other branched-chain ⁇ -keto acid analogues.
  • KIC is the metabolic precursor of leucine, the two compounds have different metabolic fates in animals.
  • KIC is absorbed mostly in the gut and utilized mostly in the liver.
  • Leucine is absorbed mostly in the stomach and is metabolized in muscle tissue.
  • KIC is also involved in steroid and carbohydrate metabolism.
  • ⁇ -keto acid analogues as animal feed supplements possesses certain disadvantages.
  • the essential amino acid L-lysine is used as a commodity feed supplement.
  • the direct keto analogue of this amino acid is non-nutritional.
  • KIC is degraded substantially by the rumen and thus has to be protected by coating or additives if used with ruminants.
  • the branched-chain ⁇ -keto acid analogues corresponding to the essential amino acids leucine, isoleucine, and valine are unstable liquids or low-melting solids with very unpleasant odors.
  • the calcium or sodium salts of the branched-chain ⁇ -keto acid analogues are the forms most commonly used as nutritive supplements. Although these salts have been shown to have the beneficial nutritive properties discussed above, they have several drawbacks: (1) bad taste; (2) unpleasant odor; (3) limited stability; and (4) degradation in the rumen. For humans, the bad taste is particularly problematic since it is difficult to mask.
  • Walser has overcome this problem in some of his patents by forming the L-lysine, L-ornithine, and/or L-histidine salts of the branched-chain ⁇ -keto acid analogues.
  • these salts are much more costly than simple metal salts.
  • 5-Substituted hydantoins are common chemical intermediates in the manufacture of branched-chain keto acid analogues. See, e.g., U.S. Pat. No. 4,069,251. They have the same carbon structure as the branched-chain keto acid analogues. However, these hydantoins are very stable powders with little odor or taste. In addition, these precursors obviously have a lower cost than the keto acid final products. The low water solubility and stability of the hydantoins should also allow them to survive the rumen better than unprotected branched-chain keto acid analogues.
  • the present invention is directed to the use of 5-alkylidene and 5-hydroxy-5-alkyl-substituted hydantoins as nutritive supplements in animal feed.
  • these classes of hydantoin analogues of essential amino acids have never previously been tested or used for such purpose.
  • 5-(2-methylthioethyl)-hydantoin the hydantoin analogue of the essential amino aicd DL-methionine
  • Thiohydantoins i.e. a hydantoin-type structure containing a sulfur atom as part of the ring structure
  • hydantoinases exist in nature that cleave urea from hydantoin rings to yield ⁇ -keto acids and amino acids. See M. Guivarch et al, Bull Soc. Chim. Fr. 1980 (1-2, Pt.2) 91-95 (CA 92: 176474); H. Yamada et al, J. Ferment. Technol. 1978 56(5), 484-91 (CA 90: 36129); U.S. Pat. No. 4,016,037; Japanese Pat. No. 70 08,633 (CA 73: 65026); H. Hasall and D.
  • Hydantoins are generally metabolized in the liver via pyrimidine pathways.
  • dihydrophyramidinase extracted from calf liver has been shown to act as a hydantoinase; see U.S. Pat. No. 3,964,970.
  • the present invention is directed to the use of 5-alkylidene and 5-hydroxy-5-alkyl substituted hydantoin analogues of essential amino acids as a new class of nutritive supplements for warm blooded animals including poultry.
  • the hydantoins conveniently are fed as additives to conventional protein-containing animal feeds. Certain embodiments of this invention are believed applicable to the attainment of particular beneficial effects and the treatment of certain disorders in animals.
  • the 5-alkylidene and/or 5-hydroxy-5-alkyl hydantoins are fed to animals in nutritionally-effective amount(s), i.e., amount(s) sufficient to enhance the nutrition of the animal.
  • hydantoins When the hydantoins are fed to achieve other beneficial results, or in the treatment of certain disorders, it again is an amount of such hydantoin(s) effective to produce the desired result which should be fed.
  • effective amounts The determination of effective amounts is well within the skill of the artisan.
  • compositions employed in the practice of the present invention comprise substituted hydantoin analogues of the essential amino acids L-valine, L-leucine, and L-isoleucine. Ingestion of these hydantoin analogues acts as a substitute for the ingestion of the analogous required essential amino acids. However, since the hydantoin analogues are absorbed and metabolized differently from the corresponding amino acids while still providing ⁇ -keto acids and amino acids for protein synthesis, special metabolic effects (beyond those produced by feeding amino acids) are obtained; these can be highly desirable and/or therapeutic.
  • the present invention is directed to food compositions containing an admixture of food proteins and nutritionally-effective amounts of one or more 5-alkylidene or 5-hydroxy-5-alkyl hydantoin analogues and the use of such hydantoin analogues as food supplements to insure proper animal nutrition, promote protein sparing, and/or treat renal and liver disease.
  • the present invention is also directed at the use of a hydantoin analogue supplement corresponding to leucine to lower serum, meat, milk, and egg yolk cholesterol; increase feed efficiency and growth; and enhance disease resistance. In every case, amounts sufficient to achieve the desired result should be fed/administered to the animal, such amounts being readily determined by the artisan.
  • the present invention is directed to the use of one or more of the 5-alkylidene and 5-hydroxy-5-alkyl substituted hydantoin analogues of essential amino acids as nutritive supplements for animals.
  • the invention comprises the use of the following hydantoin analogues:
  • the hydantoin analogues can be used to fortify low quality protein feeds to provide a balanced food, or else can be used in special, therapeutic diets that provide the minimum required protein.
  • the hydantoin analogues should be in an edible, nutritionally absorbable form, such as the free acid or its sodium, potassium, or calcium salt.
  • VH, IH, and LH are the precursors in the manufacture of the ⁇ -keto acid analogues of, respectively, valine, isoleucine, and leucine. Both 5-alkylidene-hydantoins and 5-hydroxy-5-alkyl-hydantoins yeield the ⁇ -keto acids upon hydrolysis. Consequently, the hydantoin analogues are less costly than the corresponding -keto acid analogues.
  • hydantoin analogues When used to fortify a protein-containing feed composition, hydantoin analogues can be orally administered in amounts ranging from 0.1 to 1000 milligrams (mg) per kilogram (kg) of body weight per day, the actual amount depending on the type of animal and the protein being fortified. More typically, the range is 10 to 500 mg/kg body weight/day when supplementing food that is 10 to 24% protein. These ranges correspond to 0.001-6.0 weight % of each added hydantoin analogue, based on the total dry weight of the food, or preferably 0.1-1.5% of each for large animals, such as ruminants, and 0.005-1.5% for small animals such as poultry.
  • the hydantoin analogues can be orally administered in a wide variety of manners, for example blended with a compatible carrier and in solid, powder or liquid form.
  • the analogues are blended with conventional protein-containing food for convenient administration.
  • the branched-chain hydantoin analogues VH, IH, and LH can be substituted for the corresponding essential amino acids or ⁇ -keto acids in the diet.
  • the effect of these hydantoin acids is similar to that produced by the branched chain keto acid analogues--protein sparing.
  • a minimal, mixed-quality protein diet (about 400 mg. protein/kg. body weight/day, which corresponds to about 5% protein) balanced with the needed amino acids and an effective amount (e.g. 25 to 400 mg.
  • each hydantoin analogue/kg body weight/day, preferably 50 to 200 mg.) substituted for the branched-chain keto acid analogue can sustain growth, produce protein sparing, and other beneficial metabolic effects.
  • Such diets are known to be useful for treating wasting effects, such as malnutrition and kidney and liver disease, particularly in humans.
  • LH itself can be substituted for leucine in the diet at dosages indicated above, but preferably to produce effects similar to those known to KIC.
  • beneficial effects include increased growth and feed efficiency; lowered serum, meat, milk, and egg yolk cholesterol; increased milk production; increased wool production; and enhanced disease resistance.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Substituted hydantoin analogues of essential amino acids are used as nutritive supplements in animal feed compositions.

Description

BACKGROUND OF THE INVENTION
This application is a continuation-in-part of Ser. No. 911,688 filed Sept. 25, 1986, U.S. Pat. No. 4,744,990.
This invention relates to the field of animal nutrition. In particular, the invention concerns nutritive supplements for warm-blooded animals.
It is well known that animals require proteins for their growth and health. Proteins are used to replace tissues, generate hormones, to provide the structural framework of the body (e.g. muscles, tendons, cartilage, etc..) and can also be consumed for energy.
Amino acids are the building blocks of proteins. In all living organisms, proteins and their constituent amino acids are continuously metabolized and exist in a dynamic equilibrium in the cells. Approximately 20 amino acids are common constituents of animal proteins. However, eight to ten of these amino acids are essential for the animal's survival. Since the animal's reserves of these essential amino acids are normally depleted within a few hours, the animmal must replenish its supply by ingesting proteins containing appropriate amounts of essential amino acids. The nutritional value of proteins used in aminal feed is therefore a function of the presence of these essential amino acids in proper amounts. However, feeds containing proteins of low nutritional value, i.e. deficient in one or more essential amino acids, can be supplemented with those amino acids or with other proteins containing the needed amino acids in order to attain the proper balance and enhance the nutrient usability of the proteins. Thus, plant proteins such as wheat, corn, and soybeans are commonly fortified with L-lysine, DL-methionine and/or other essential amino acids to upgrade the nutritional value of these common animal feeds.
It has been shown that the α-keto acid analogues of most of the essential amino acids can substitute for the corresponding amino acid in the diets of rats and men; see J. L. Wood and S. L. Cooley, Proc. Soc. Exp. Biol. Med. 85, 409-411 (1954), and J. H. Close, N. Engl. J. Med., 290: 663-667 (1974). In 1973 Dr. MacKenzie Walser of Johns Hopkins University proposed using α-keto acid analogues as non-nitrogen supplements to protein-reduced diets for kidney disease patients, who have difficulty eliminating nitrogen wastes. In the subsequent research, it was observed that the use of the keto analogues of the branched-chain essential amino acids leucine, isoleucine, and valine has a "protein-sparing" effect, i.e. use of these compounds prevented the body from using up amino acids in existing protein, thereby avoiding weight loss. The existing knowledge on the use of branched-chain α-keto acid analogues in humans was reviewed by Walser in J. Parenteral and Enteral Nutrition, 8(1), 37-41 (1983).
______________________________________                                    
AMINO ACID       α-KETO ACID ANALOGUE                               
______________________________________                                    
 ##STR1##                                                                 
                  ##STR2##                                                
Example:                                                                  
R = (CH.sub.3).sub.2 CH (isopropyl group)                                 
 ##STR3##                                                                 
                  ##STR4##                                                
valine           α-keto-isovaleric acid                             
______________________________________                                    
The work of Walser on the use of branched-chain keto acid analogues as a nutritional substitute in humans has recently been extended to the field of animal nutrition. Dr. Steven Nissan of Iowa State University has shown that the use of the keto analogue of leucine, α-keto-isocaproic acid (KIC), apparently has beneficial effects when used as a food supplement for livestock. Wallaces Farmer (June 14, 1986); Pro Farmer (May 24, 1986). Among the advantages claimed when KIC is substituted for most of the diet leucine are: (1) increased feed efficiency and growth, particularly in ruminants; (2) improved quality and production of milk; (3) reduced cholesterol, particularly in eggs and milk; (4) increased wool production in sheep; and (5) increased immunological response.
It should be noted that KIC has special properties which distinguish it from other branched-chain α-keto acid analogues. Although KIC is the metabolic precursor of leucine, the two compounds have different metabolic fates in animals. KIC is absorbed mostly in the gut and utilized mostly in the liver. Leucine is absorbed mostly in the stomach and is metabolized in muscle tissue. KIC is also involved in steroid and carbohydrate metabolism.
The use of α-keto acid analogues as animal feed supplements possesses certain disadvantages. For example, the essential amino acid L-lysine is used as a commodity feed supplement. However, the direct keto analogue of this amino acid is non-nutritional. Another problem is that KIC is degraded substantially by the rumen and thus has to be protected by coating or additives if used with ruminants.
In addition, the branched-chain α-keto acid analogues corresponding to the essential amino acids leucine, isoleucine, and valine are unstable liquids or low-melting solids with very unpleasant odors. The calcium or sodium salts of the branched-chain α-keto acid analogues are the forms most commonly used as nutritive supplements. Although these salts have been shown to have the beneficial nutritive properties discussed above, they have several drawbacks: (1) bad taste; (2) unpleasant odor; (3) limited stability; and (4) degradation in the rumen. For humans, the bad taste is particularly problematic since it is difficult to mask. Walser has overcome this problem in some of his patents by forming the L-lysine, L-ornithine, and/or L-histidine salts of the branched-chain α-keto acid analogues. However, these salts are much more costly than simple metal salts. The unpleasant odor of branched-chain keto acid analogue salts, especially when contacted with the skin or other moist environment, makes branched-chain α-keto acid analogues' use objectionable to those who handle and administer the supplements.
It is the object of this invention to provide nutritional supplements for animal feeds which do not have the foregoing disadvantages of branched-chain keto acid analogues. It is believed that the 5-alkylidene and 5-hydroxy-5-alkyl substituted hydantoin analogues of the essential amino acids can serve such a purpose.
5-Substituted hydantoins are common chemical intermediates in the manufacture of branched-chain keto acid analogues. See, e.g., U.S. Pat. No. 4,069,251. They have the same carbon structure as the branched-chain keto acid analogues. However, these hydantoins are very stable powders with little odor or taste. In addition, these precursors obviously have a lower cost than the keto acid final products. The low water solubility and stability of the hydantoins should also allow them to survive the rumen better than unprotected branched-chain keto acid analogues.
______________________________________                                    
                       5-SUBSTITUTED                                      
           KETO ACID   HYDANTOIN                                          
AMINO ACID ANALOGUE    ANALOGUE                                           
______________________________________                                    
 ##STR5##                                                                 
            ##STR6##                                                      
                        ##STR7##                                          
Example                                                                   
 ##STR8##                                                                 
5-isopropylidene-hydantoin                                                
______________________________________                                    
The present invention is directed to the use of 5-alkylidene and 5-hydroxy-5-alkyl-substituted hydantoins as nutritive supplements in animal feed. As far as is known to applicants, these classes of hydantoin analogues of essential amino acids have never previously been tested or used for such purpose. However, it should be noted that 5-(2-methylthioethyl)-hydantoin, the hydantoin analogue of the essential amino aicd DL-methionine, has been used as an animal feed supplement to improve feed efficiency. See U.S. Pat. No. 3,644,629. Thiohydantoins (i.e. a hydantoin-type structure containing a sulfur atom as part of the ring structure) have also been used as animal feed additives to regulate metabolism and increase the conversion ratio of nutrients, South African 68/7562.
The carbon structure of the hydantoins which are the subject of this invention is stabilized through cyclization with a urea moiety. Enzymes called hydantoinases exist in nature that cleave urea from hydantoin rings to yield α-keto acids and amino acids. See M. Guivarch et al, Bull Soc. Chim. Fr. 1980 (1-2, Pt.2) 91-95 (CA 92: 176474); H. Yamada et al, J. Ferment. Technol. 1978 56(5), 484-91 (CA 90: 36129); U.S. Pat. No. 4,016,037; Japanese Pat. No. 70 08,633 (CA 73: 65026); H. Hasall and D. M. Greensberg, J. Bacteriol. 81, 755-61 (1961) (CA 55: 20088); R. C. Valentine and R. S. Wolfe, Biochem. Biophys. Res. Common. 5(4), 305-308 (1961). Hydantoins are generally metabolized in the liver via pyrimidine pathways. Thus, dihydrophyramidinase extracted from calf liver has been shown to act as a hydantoinase; see U.S. Pat. No. 3,964,970.
SUMMARY OF THE INVENTION
The present invention is directed to the use of 5-alkylidene and 5-hydroxy-5-alkyl substituted hydantoin analogues of essential amino acids as a new class of nutritive supplements for warm blooded animals including poultry. The hydantoins conveniently are fed as additives to conventional protein-containing animal feeds. Certain embodiments of this invention are believed applicable to the attainment of particular beneficial effects and the treatment of certain disorders in animals. As nutritive supplements, the 5-alkylidene and/or 5-hydroxy-5-alkyl hydantoins are fed to animals in nutritionally-effective amount(s), i.e., amount(s) sufficient to enhance the nutrition of the animal. When the hydantoins are fed to achieve other beneficial results, or in the treatment of certain disorders, it again is an amount of such hydantoin(s) effective to produce the desired result which should be fed. The determination of effective amounts is well within the skill of the artisan.
The preferred compositions employed in the practice of the present invention comprise substituted hydantoin analogues of the essential amino acids L-valine, L-leucine, and L-isoleucine. Ingestion of these hydantoin analogues acts as a substitute for the ingestion of the analogous required essential amino acids. However, since the hydantoin analogues are absorbed and metabolized differently from the corresponding amino acids while still providing α-keto acids and amino acids for protein synthesis, special metabolic effects (beyond those produced by feeding amino acids) are obtained; these can be highly desirable and/or therapeutic.
As protein supplements, the present invention is directed to food compositions containing an admixture of food proteins and nutritionally-effective amounts of one or more 5-alkylidene or 5-hydroxy-5-alkyl hydantoin analogues and the use of such hydantoin analogues as food supplements to insure proper animal nutrition, promote protein sparing, and/or treat renal and liver disease. The present invention is also directed at the use of a hydantoin analogue supplement corresponding to leucine to lower serum, meat, milk, and egg yolk cholesterol; increase feed efficiency and growth; and enhance disease resistance. In every case, amounts sufficient to achieve the desired result should be fed/administered to the animal, such amounts being readily determined by the artisan.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to the use of one or more of the 5-alkylidene and 5-hydroxy-5-alkyl substituted hydantoin analogues of essential amino acids as nutritive supplements for animals. In particular, the invention comprises the use of the following hydantoin analogues:
              TABLE I                                                     
______________________________________                                    
Essential                                                                 
Amino Acid Hydantoin Analogue                                             
______________________________________                                    
L-valine   5-isopropylidene-hydantoin, or                                 
                                (VH)                                      
           5-hydroxy-5-isopropyl-hydantoin                                
L-isoleucine                                                              
           5-sec-butylidene-hydantoin, or                                 
                                (IH)                                      
           5-hydroxy-5-sec-butyl-hydantoin                                
L-leucine  5-isobutylidene-hydantoin, or                                  
                                (LH)                                      
           5-hydroxy-5-isobutyl-hydantoin                                 
______________________________________                                    
Instead of the corresponding α-keto acid or amino acid, the hydantoin analogues can be used to fortify low quality protein feeds to provide a balanced food, or else can be used in special, therapeutic diets that provide the minimum required protein. The hydantoin analogues should be in an edible, nutritionally absorbable form, such as the free acid or its sodium, potassium, or calcium salt. VH, IH, and LH are the precursors in the manufacture of the α-keto acid analogues of, respectively, valine, isoleucine, and leucine. Both 5-alkylidene-hydantoins and 5-hydroxy-5-alkyl-hydantoins yeield the α-keto acids upon hydrolysis. Consequently, the hydantoin analogues are less costly than the corresponding -keto acid analogues.
When used to fortify a protein-containing feed composition, hydantoin analogues can be orally administered in amounts ranging from 0.1 to 1000 milligrams (mg) per kilogram (kg) of body weight per day, the actual amount depending on the type of animal and the protein being fortified. More typically, the range is 10 to 500 mg/kg body weight/day when supplementing food that is 10 to 24% protein. These ranges correspond to 0.001-6.0 weight % of each added hydantoin analogue, based on the total dry weight of the food, or preferably 0.1-1.5% of each for large animals, such as ruminants, and 0.005-1.5% for small animals such as poultry.
The hydantoin analogues can be orally administered in a wide variety of manners, for example blended with a compatible carrier and in solid, powder or liquid form. Preferably, the analogues are blended with conventional protein-containing food for convenient administration.
In another embodiment of the invention, the branched-chain hydantoin analogues VH, IH, and LH can be substituted for the corresponding essential amino acids or α-keto acids in the diet. The effect of these hydantoin acids is similar to that produced by the branched chain keto acid analogues--protein sparing. A minimal, mixed-quality protein diet (about 400 mg. protein/kg. body weight/day, which corresponds to about 5% protein) balanced with the needed amino acids and an effective amount (e.g. 25 to 400 mg. of each hydantoin analogue/kg body weight/day, preferably 50 to 200 mg.) substituted for the branched-chain keto acid analogue, can sustain growth, produce protein sparing, and other beneficial metabolic effects. Such diets are known to be useful for treating wasting effects, such as malnutrition and kidney and liver disease, particularly in humans.
LH itself can be substituted for leucine in the diet at dosages indicated above, but preferably to produce effects similar to those known to KIC. Such beneficial effects (beside protein-sparing) include increased growth and feed efficiency; lowered serum, meat, milk, and egg yolk cholesterol; increased milk production; increased wool production; and enhanced disease resistance.

Claims (15)

We claim:
1. A method of feeding warm-blooded animals including poultry comprising administering thereto a nutritionally-effective amount of a 5-alkylidene, or 5-hydroxy-5-alkyl, substituted hydantoin analogue of an α-keto acid analogue of valine, isoleucine or leucine.
2. A method of claim 1 wherein the nutritionally effective amount is 0.1 to 1000 mg per kg of body weight per day.
3. A method of claim 1 wherein the hydantoin analogue is selected from
(a) 5-isopropylidene-hydantoin,
(b) 5-hydroxy-5-isopropyl-hydantoin,
(c) 5-isobutylidene-hydantoin,
(d) 5-hydroxy-5-isobutyl-hydantoin,
(e) 5-sec-butylidene-hydantoin, and
(f) 5-hydroxy-5-sec-butyl-hydantoin.
4. A method of claim 1 wherein said hydantoin analogue is in the form of its sodium, potassium or calcium salt.
5. A method of claim 3 wherein said hydantoin analogue is in the form of its sodium, potassium or calcium salt.
6. A method of claim 1 further comprising simultaneously administering to the animal a protein-containing food material.
7. A method of claim 6 wherein said food material comprises one or more of wheat, corn and soybean protein.
8. An improved protein-containing food composition for warm-blooded animals, the improvement comprising the admixture with protein containing food materials of a nutritionally-effective amount of a 5-alkylidene or 5-hydroxy-5-alkyl substituted hydantoin analogue of valine, isoleucine or leucine.
9. A food composition of claim 8 wherein the hydantoin analogue is selected from
(a) 5-isopropylidene-hydantoin,
(b) 5-hydroxy-5-isopropyl-hydantoin,
(c) 5-isobutylidene-hydantoin,
(d) 5-hydroxy-5-isobutyl-hydantoin,
(e) 5-sec-butylidene-hydantoin, and
(f) 5-hydroxy-5-sec-butyl-hydantoin.
10. A food composition of claim 8 wherein the substituted hydantoin analogue is in the form of its sodium, potassium or calcium salt.
11. A food composition of claim 9 wherein the substituted hydantoin analogue is in the form of its sodium, potassium or calcium salt.
12. A food composition of claim 8 comprising 0.001 to 6 percent by weight of said substituted hydantoin based on the total dry weight of the food composition.
13. A food composition of claim 8 comprising 0.005 to 1.5 percent by weight of said substituted hydantoin based on the total dry weight of the food composition.
14. A food composition claim 8 wherein the hydantoin analogue is 5-isobutylidene hydantoin.
15. A food composition of claim 8 wherein the hydantoin analogue is 5-hydroxy-5-isobutyl-hydantoin.
US07/174,651 1986-09-25 1988-03-29 Hydantoins as animal food supplements Expired - Lifetime US4871552A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/174,651 US4871552A (en) 1986-09-25 1988-03-29 Hydantoins as animal food supplements

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/911,688 US4744990A (en) 1986-09-25 1986-09-25 Hydantoins as animal food supplements
US07/174,651 US4871552A (en) 1986-09-25 1988-03-29 Hydantoins as animal food supplements

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06/911,688 Continuation-In-Part US4744990A (en) 1986-09-25 1986-09-25 Hydantoins as animal food supplements

Publications (1)

Publication Number Publication Date
US4871552A true US4871552A (en) 1989-10-03

Family

ID=26870427

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/174,651 Expired - Lifetime US4871552A (en) 1986-09-25 1988-03-29 Hydantoins as animal food supplements

Country Status (1)

Country Link
US (1) US4871552A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183674A (en) * 1988-12-02 1993-02-02 Thomas Olin Food and feedstuff
US5707837A (en) * 1995-08-09 1998-01-13 Degussa Aktiengesellschaft Method of producing (R)-tertiary leucine
US6358546B1 (en) * 1999-01-15 2002-03-19 Ralston Purina Company Methods for customizing pet food

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA669828A (en) * 1963-09-03 Tchelitcheff Serge Animal feeding stuffs
DE1965921A1 (en) * 1968-11-20 1971-08-12 Hoechst Ag Thiohydantoins as feed conversion improving
US3868456A (en) * 1971-05-15 1975-02-25 Farmaceutici Italia Certain hydantoins having animal growth stimulating activity
US3964970A (en) * 1973-05-11 1976-06-22 Snam Progetti S.P.A. Process for the preparation of L-car-bamyl-amino acids and of the corresponding L-amino acids
US4065571A (en) * 1974-06-11 1977-12-27 Canada Packers Limited Antiviral 5-(substituted benzal) hydantoins
US4100161A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
US4175198A (en) * 1976-10-07 1979-11-20 W. R. Grace & Co. 5-Secondary alkylidene hydantoins
US4228099A (en) * 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4230709A (en) * 1978-05-23 1980-10-28 Lilly Industries Limited Method of treating asthma with alkyl, alkylidene and alkylene hydantoins
US4296127A (en) * 1979-04-18 1981-10-20 The Johns Hopkins University Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof
US4320146A (en) * 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4352814A (en) * 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4744990A (en) * 1986-09-25 1988-05-17 W. R. Grace & Co. Hydantoins as animal food supplements

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA669828A (en) * 1963-09-03 Tchelitcheff Serge Animal feeding stuffs
DE1965921A1 (en) * 1968-11-20 1971-08-12 Hoechst Ag Thiohydantoins as feed conversion improving
US3868456A (en) * 1971-05-15 1975-02-25 Farmaceutici Italia Certain hydantoins having animal growth stimulating activity
US3964970A (en) * 1973-05-11 1976-06-22 Snam Progetti S.P.A. Process for the preparation of L-car-bamyl-amino acids and of the corresponding L-amino acids
US4100293A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
US4100161A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
US4065571A (en) * 1974-06-11 1977-12-27 Canada Packers Limited Antiviral 5-(substituted benzal) hydantoins
US4175198A (en) * 1976-10-07 1979-11-20 W. R. Grace & Co. 5-Secondary alkylidene hydantoins
US4228099A (en) * 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4320146A (en) * 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4230709A (en) * 1978-05-23 1980-10-28 Lilly Industries Limited Method of treating asthma with alkyl, alkylidene and alkylene hydantoins
US4296127A (en) * 1979-04-18 1981-10-20 The Johns Hopkins University Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof
US4352814A (en) * 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4744990A (en) * 1986-09-25 1988-05-17 W. R. Grace & Co. Hydantoins as animal food supplements

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
Bull. Soc. Chim. Fr., 1980 (1 2, Pt. 2), 91 95 (CA 92:176474). *
Bull. Soc. Chim. Fr., 1980 (1-2, Pt. 2), 91-95 (CA 92:176474).
Chem. Abst. 87:4028j, vol. 87, p. 336 (Mitsugi et al., U.S. Pat. No. 4,016,037). *
Fermentations 65026q, vol. 73, 1970, p. 219 (Nakayama et al., 70,08633). *
ISU Press Release (May 19, 1986). *
J. Bacteriol., 81, 755 761 (1961), C. T. Gray et al., Biochem, Biophys. Res. Commun., 5(4), 305 308 (1961), R. C. Valentine et al. *
J. Bacteriol., 81, 755-761 (1961), C. T. Gray et al., Biochem, Biophys. Res. Commun., 5(4), 305-308 (1961), R. C. Valentine et al.
J. Biol. Chem. (238(10), 3325 3329 (1963), H. Hassall et al. *
J. Biol. Chem. (238(10), 3325-3329 (1963), H. Hassall et al.
J. Ferment Technol., 1978, 56(5), 484 491 (CA 90:36129), H. Yamada et al. *
J. Ferment Technol., 1978, 56(5), 484-491 (CA 90:36129), H. Yamada et al.
Jour. Parenteral and Enteral Nutrition 8(1), 37 4, Rationale and Indications for the Use of Keto Analogues (1983). *
Jour. Parenteral and Enteral Nutrition 8(1), 37-4, "Rationale and Indications for the Use of α-Keto Analogues" (1983).
N.E. Jour. Med., 311(10), 623 629, The Effect of Keto Acid Amino Acid Supplement to a Restricted Diet on the Progression of Chronic Renal Failure (1984). *
N.E. Jour. Med., 311(10), 623-629, "The Effect of Keto Acid-Amino Acid Supplement to a Restricted Diet on the Progression of Chronic Renal Failure" (1984).
New Aspects of Clinical Nutrition, pp. 319 324 (Basel, 1983), Nitrogen Sparing Effects of Branched Chain Ketoacids . *
New Aspects of Clinical Nutrition, pp. 319-324 (Basel, 1983), "Nitrogen Sparing Effects of Branched Chain Ketoacids".
New England Jour. Med., 290:663 667, 1974, The Use of Amino Acid Precursors in Nitrogen Accumulation Diseases . *
New England Jour. Med., 290:663-667, 1974, "The Use of Amino Acid Precursors in Nitrogen-Accumulation Diseases".
Pro Farmer (May 24, 1986). *
Proc. Soc. Exp. Biol. Med., 85:409 411 (1954), Substitution of Keto Acids for Five Amino Acids Essential for Growth of the Rat . *
Proc. Soc. Exp. Biol. Med., 85:409-411 (1954), "Substitution of α-Keto Acids for Five Amino Acids Essential for Growth of the Rat".
Wallaces Farmer (Jun. 14, 1986). *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183674A (en) * 1988-12-02 1993-02-02 Thomas Olin Food and feedstuff
US5346707A (en) * 1988-12-02 1994-09-13 Thomas Olin Food and feedstuff
US5707837A (en) * 1995-08-09 1998-01-13 Degussa Aktiengesellschaft Method of producing (R)-tertiary leucine
US6358546B1 (en) * 1999-01-15 2002-03-19 Ralston Purina Company Methods for customizing pet food

Similar Documents

Publication Publication Date Title
US5028440A (en) Method of raising meat producing animals to increase lean tissue development
US5030657A (en) L-carnitine supplemented catfish diet
US5087472A (en) Feed compositions for domestics animals containing hydroxymethylbutyrate
RU2341972C2 (en) Application guanidinoacetic acid as fodder additive
Smith et al. Heat increment associated with dietary protein, fat, carbohydrate and complete diets in salmonids comparative energetic efficiency
US5124357A (en) Carnitine supplemented finishing pig diet
Leveille et al. Amino acid requirements for maintenance in the adult rooster: II. The requirements for glutamic acid, histidine, lysine and arginine
CA1070158A (en) Pro-amino acid supplements
WO2019185408A1 (en) Use of guanidinoacetic acid and/or creatine in aquaculture
Luecke et al. The relationship of nicotinic acid, tryptophane and protein in the nutrition of the pig
Borg et al. Species and isomeric variation in the utilization of amino acids
Yokogoshi et al. Some factors affecting the nitrogen sparing action of methionine and threonine in rats fed a protein free diet
Zhao et al. Comparative study on the utilization of different methionine sources by channel catfish, Ictalurus punctatus (Rafinesque, 1818)
US4871552A (en) Hydantoins as animal food supplements
US4744990A (en) Hydantoins as animal food supplements
CA2547911A1 (en) Dietary non-essential amino acid tyrosine regulates the body weight of animals through regulating the animal appetite or food intake
Abe et al. Absence of limiting amino acids in calves fed a corn and soybean meal diet past three months of age
HU184104B (en) Food-composition for poultry for promoting their growth
Vree et al. Acetylation and hydroxylation of sulphatroxazole by the turtle Pseudemys scripta elegans
Hrubý The amino acid maintenance and growth requirements of male broilers
Thinh Supplementation of Milo-Soy Creep Rations with Methionine And/Or Lysine
Chowdhury et al. Urea in poultry nutrition-Review
Jankela et al. Nitrogen excretion in Japanese quail during protein depletion and repletion
Parsons et al. Relative lysine potencies of eight analogues in diets of young turkeys
HU202750B (en) Process for producing composition for improving growth of animals and utility of their feeding

Legal Events

Date Code Title Description
AS Assignment

Owner name: W. R. GRACE & CO.-CONN., 55 HAYDEN AVENUE, LEXINGT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:BRAGDON, ROBERT W.;GAUDETTE, ROGER R.;REEL/FRAME:004977/0911

Effective date: 19881116

Owner name: W. R. GRACE & CO.-CONN., A CORP. OF CT., MASSACHUS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRAGDON, ROBERT W.;GAUDETTE, ROGER R.;REEL/FRAME:004977/0911

Effective date: 19881116

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: W. R. GRACE & CO.-CONN., MASSACHUSETTS

Free format text: MERGER;ASSIGNORS:GRACE MERGER CORP. A CT CORP. (MERGED INTO);W. R. GRACE & CO. A CT. CORP.;REEL/FRAME:005206/0001

Effective date: 19880525

AS Assignment

Owner name: CHASE MANHATTAN BANK (NATIONAL ASSOCIATION), AS CO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HAMPSHIRE CHEMICAL CORP.;REEL/FRAME:006621/0379

Effective date: 19921229

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: HAMPSHIRE CHEMICAL CORP., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:W.R. GRACE & CO.-CONN.;REEL/FRAME:006467/0595

Effective date: 19921229

AS Assignment

Owner name: CHEMICAL BANK, NEW YORK

Free format text: ASSIGNMENT FOR SECURITY;ASSIGNOR:HAMPSHIRE CHEMICAL CORPORATION;REEL/FRAME:007662/0410

Effective date: 19950908

Owner name: HAMPSHIRE CHEMICAL CORPORATION, MASSACHUSETTS

Free format text: PATENT RELEASE;ASSIGNOR:CHASE MANHATTAN BANK, THE;REEL/FRAME:007677/0852

Effective date: 19950831

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: HAMPSHIRE CHEMICAL CORP., MAINE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHASE MANHATTAN BANK, THE;REEL/FRAME:009227/0565

Effective date: 19980330

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 12